Actinobacteria-based biocontrol solutions for Fusarium diseases in crops

Overview

This research program investigates the use of soil-dwelling Actinobacteria, particularly genera such as Streptomyces, as biological control agents against Fusarium pathogens. Fusarium species cause significant crop losses through root rot in field pea and head blight in small grain cereals, and current management options are limited. Actinobacteria are prolific producers of secondary metabolites and are naturally adapted to soil environments due to their filamentous growth, which allows them to navigate air pockets and soil discontinuities more effectively than many other bacteria. The goal is to identify new strains and bioactive chemistries that can suppress Fusarium in agricultural soils, offering a sustainable alternative or complement to existing disease management strategies.

Technical specifications

Research approach:

• Isolation of diverse Actinobacteria from soil samples to build a candidate strain library
• High-throughput screening using a rapid, clean growth pouch assay for Fusarium avenaceum root rot on field pea
• Secondary screening of promising strains in pot-based trials under more realistic growing conditions
• Established protocols for evaluating Fusarium graminearum as a head blight pathogen of small grain cereals
• Prior experience characterizing interactions between Fusarium and Actinobacteria, including effects on mycotoxins produced by F. graminearum

Key advantages of Actinobacteria as biocontrol candidates:

• Filamentous growth enables colonization of heterogeneous soil environments
• Well-documented capacity to produce diverse secondary metabolites with antimicrobial activity
• Native soil competency supports persistence and activity in the target environment

Technology readiness level

The program is at an early-to-mid discovery stage. Core screening assays for both Fusarium avenaceum root rot on field pea and Fusarium graminearum head blight on cereals are already established and operational. Initial strain isolations and pouch-based screening are underway, with pot-scale validation planned as a next step. No field-scale or commercial product formulation has been developed yet, and further work is needed to confirm efficacy, consistency, and practical delivery methods before any commercial application can be pursued.